In 2011, a systematic review that concerned the use of pentoxifylline in patients with NASH [99] demonstrated that pentoxifylline seems to decrease both AST and ALT levels but cannot influence cytokine levels and histological aspects of NASH (see Table 7). This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.